1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. MARKSANS PHARMA LTD.

Marksans Pharma Ltd.

NSE: MARKSANS | BSE: 524404

Slowing Down Stock
Download real time

194.40 -3.21 (-1.62%)

45.80% Fall from 52W High

687.0K NSE+BSE Volume

NSE 13 Mar, 2025 3:31 PM (IST)

Watchlist

Portfolio

Alert

Share
11S
10W
6O
1T
8,809.5

Market Cap

Above industry Median
23.9

PE TTM

Below industry Median
1.5

PEG TTM

PEG TTM is much higher than 1
3.9

Price to Book

Above industry Median
1.1

Beta 1Year

High Volatility


Board Meetings - Marksans Pharma Ltd.

The latest board meeting for Marksans Pharma Ltd. took place on 11 Feb 2025, for the purpose of Quarterly Results

Share
Ex-date Purpose Notes
11 Feb 2025 Quarterly Results -
12 Nov 2024 Quarterly Results -
13 Aug 2024 Quarterly Results -
30 May 2024 Audited Results & Final Dividend -
13 Feb 2024 Quarterly Results -
09 Nov 2023 Quarterly Results -
11 Aug 2023 Quarterly Results -
30 May 2023 Audited Results & Final Dividend -
13 Feb 2023 Quarterly Results -
20 Jan 2023 Others Inter alia, to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis.
14 Nov 2022 Quarterly Results -
13 Aug 2022 Quarterly Results -
08 Jul 2022 Buy Back of shares -
30 May 2022 Audited Results & Final Dividend -
11 Feb 2022 Quarterly Results -
10 Nov 2021 Quarterly Results (Revised)
11 Aug 2021 Quarterly Results -
23 Jul 2021 To consider issue of Warrants -
15 Jun 2021 To consider Issue of Warrants To consider issuance of convertible warrants on preferential basis.
31 May 2021 Audited Results & Final Dividend -
08 Feb 2021 Quarterly Results -
06 Nov 2020 Quarterly Results -
04 Aug 2020 Quarterly Results -
02 Jun 2020 Audited Results & Final Dividend -
11 Feb 2020 Quarterly Results -
12 Nov 2019 Quarterly Results -
09 Aug 2019 Quarterly Results -
29 May 2019 Audited Results & Final Dividend -
08 Feb 2019 Quarterly Results -
13 Nov 2018 Half Yearly Results -
06 Aug 2018 Unaudited Financial Results -
30 May 2018 Audited Results & Dividend -
12 Feb 2018 Quarterly Results -
13 Nov 2017 Quarterly Results -
11 Aug 2017 Quarterly Results -
29 May 2017 Audited Results & Dividend -
06 Feb 2017 Quarterly Results -
12 Nov 2016 Quarterly Results -
13 Aug 2016 Quarterly Results -
30 May 2016 Audited Results & Dividend -
12 Feb 2016 Quarterly Results -
10 Nov 2015 Quarterly Results -
08 Aug 2015 Quarterly Results -
30 May 2015 Audited Results & Dividend -
07 Feb 2015 Quarterly Results -
31 Oct 2014 Quarterly Results -
12 Aug 2014 Quarterly Results -
29 May 2014 Audited Results & Dividend -
03 Feb 2014 Quarterly Results -
31 Oct 2013 Quarterly Results -
29 Jul 2013 Quarterly Results -
27 May 2013 Audited Results -
14 Feb 2013 Quarterly Results -
14 Dec 2012 To consider conversion of warrant&issue To consider conversion of warrants and issue and allot in lieu thereof 1,75,00,000 Equity Shares of Re. 1/- each to promoter on preferential allotment basis .
12 Nov 2012 Quarterly Results -
14 Aug 2012 Quarterly Results -
29 May 2012 Audited Results -
13 Feb 2012 Quarterly Results -
14 Nov 2011 Quarterly Results -
12 Aug 2011 Quarterly Results -
28 Jun 2011 Audited Results -
28 May 2011 Audited Results (Revised)
14 Feb 2011 Quarterly Results (Revised)
15 Nov 2010 Quarterly Results -
12 Aug 2010 Audited & Quarterly Results -
07 May 2010 Quarterly Results -
14 Apr 2010 Conversion of Bonds The Board has converted the 1 Bond of US$ 1000 into 1,333 Equity Shares of Re. 1/- each & allotted to the concerned bond holder. Accordingly, Paid-up Equity Share Capital of the Company has increased.
29 Jan 2010 Quarterly Results -
29 Dec 2009 To consider Raising of Capital To raise capital through issue of Equity Shares and/or Equity Shares through depository receipts and/or FCCB's and/or any other CB's / Securities upto an amount not exceeding USD125 Million.
30 Oct 2009 Quarterly Results & Others To raise capital through issue of Equity or Equity linked instruments upto Rs. 200 Crs & to restructure business model of the Company, hiving off API division of the Company.
31 Jul 2009 Quarterly Results -
29 Jun 2009 Audited Results -
31 Jan 2009 Quarterly Results -
31 Oct 2008 Quarterly Results -
23 Sep 2008 Others To make allotment of 8400241 Equity Shares of Rs 1/- to M/s. Bamacle LLc on Preferential allotment basis, has been postponed to be held on September 23, 2008. (Revised)
16 Sep 2008 Allotment of equity shares To allot 8400241 Equity shares of Re 1/- to M/s. Bamacle LLc on preferential allotment basis, if approved by the shareholders at the Extra Ordinary General Meeting to be held on September 10, 2008.
02 Sep 2008 Audited Results & Others To consider and approve ESOP scheme for the employees of the Company & to fix the day, date, time and place of the Annual General Meeting.
27 Aug 2008 Others To acquire entire shareholding of M/s. Relonchem Ltd.
11 Aug 2008 Allotment of equity shares To allot 84,00,241 Equity shares of Rs 1/- each at a premium of Rs 19.12/- each of the Co., aggregating to an amount not exceeding Rs 16,89,87,000/- to Barnacle LLC, on preferential allotment basis.
31 Jul 2008 Quarterly Results -
30 Apr 2008 Quarterly Results -
27 Mar 2008 To consider Redemption of CRPS To consider and approve redemption of Cumulative Redeemable Preference Shares issued by the Company and due for redemption on March 27, 2008.
29 Feb 2008 Others To declare the results of the postal ballot and to decide the record date for the purpose of sub - division of the Equity shares of the Company.
25 Jan 2008 Quarterly Results & Stock Split -
31 Oct 2007 Quarterly Results -
31 Aug 2007 Audited Results & Others 1. To consider appointment of Statutory Auditors of the Company. 2. To approve the draft of notice of the AGM. 3. Fix the day, date, time and place of the AGM. 4. To fix book Closure dates.
31 Jul 2007 Quarterly Results -
30 Apr 2007 Quarterly Results -
31 Jan 2007 Quarterly Results -
30 Oct 2006 Quarterly Results -
31 Jul 2006 Quarterly Results -
29 Jun 2006 Accounts, Amalgamation & Others 1. Approve issue of securities in the form of ADR / GDR / FCCB's. 2. Approve Amalgamation of Mark Remedies Ltd (Transferor Company) (100% subsidiary of the Company) with the Company (Transferee Co.)
31 Jan 2006 Quarterly Results -
29 Oct 2005 Quarterly Results -
18 Oct 2005 Allotment of shares Allotment of shares to the shareholders of transferor Company pursuant to approved scheme of amalgamation.
06 Oct 2005 To consider change of name of the co. To consider shifting of Registered office of the company & Decided to change the name of the company pursuant to Scheme of Amalgamation to M/s Marksans Pharma Ltd.
28 Jul 2005 Quarterly Results -
28 Apr 2005 Quarterly Results -
14 Apr 2005 To consider issue of FCCB's/GDR To consider issue of Foreign Currency Convertible Bonds /GDR for financing acquisitions in the US and Europe or elsewhere.
18 Mar 2005 Others To consider & approve Memorandum of Understanding (MoU) entered with Glenmark Laboratories Ltd .